Why the study?
Does adjuvant treatment with trastuzumab increase the risk of congestive heart failure in patients with early breast cancer?
Does adjuvant treatment with trastuzumab increase the risk of congestive heart failure in patients with early breast cancer?
Adjuvant trastuzumab in early breast cancer carries a risk of congestive heart failure, necessitating careful risk-benefit analysis and routine cardiac monitoring.
Answers are grounded in this paper and cite their sources.
Reinforces cardiac monitoring in trastuzumab use; confirms CHF risk elevation via Level 1 meta-analysis.
This comprehensive meta-analysis evaluated the risk of congestive heart failure with a usage profile of adjuvant trastuzumab in patients with early breast cancer. Before initiating treatment with trastuzumab, a risk-benefit analysis for individual patients should be critically evaluated, considering that the prognosis is closely related to drug dose and duration of use. Cardiac function should be monitored throughout the treatment period and also during follow-up. Thus, early identification of trastuzumab-related cardiac dysfunction can allow effective medical intervention, elimination of symptoms, recovery of function, and continuation of trastuzumab therapy.
No takes yet. Share an insight, caveat, or question.
Long et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: